The Relationship between Prostate-specific Antigen, Invasiveness and Vascular Endothelial Growth Factor in Human Prostatic Cancer.
- Author:
Hyoung Jin KIM
1
;
Dong Sun KIM
;
Duck Ki YUN
;
Jae Heung CHO
;
Cheol Whan KIM
;
Jong Bo CHOI
Author Information
1. Departments of Urology and 1Pathology, Korea University College of Medicine, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Prostate cancer;
Vascular endothelial growth factor;
Angiogenesis Prostate-specific antigen
- MeSH:
Angiogenesis Inducing Agents;
Humans*;
Neovascularization, Pathologic;
Paraffin;
Prostate-Specific Antigen*;
Prostatectomy;
Prostatic Neoplasms*;
Recurrence;
Vascular Endothelial Growth Factor A*
- From:Korean Journal of Urology
2001;42(6):621-626
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Vascular endothelial growth factor (VEGF) known as an angiogenic factor is a potent inducer of pathologic neovascularization. The purpose of this study is identifying the relationship between serum PSA, invasiveness and VEGF expression in prostatic cancer. MATERIALS AND METHODS: Ex-vivo study with immunohistochemical stain analysis for VEGF expression was performed on 18 paraffin embedded specimens of prostatic cancer patients who were treated with radical prostatectomy. VEGF expressions were classified by three groups (1+ , 2+ , 3+ ) according to the degree of staining of cancer cell. Biochemical failure and recurrence were determined by Takayama's IMx PSA assay criterion (>0.1ng/ml) following radical prostatectomy. RESULTS: Immunohistochemical studies demonstrated that each group contained 1, 2, 8 patients in advanced disease (n=11), and 3, 2, 2 patients in localized disease (n=7), respectively. All cases in strong positive (3+ ) group had Gleason sum higher than 7 and nadir PSA values were lower than 0.1ng/ml except one case. We found no correlation between initial PSA and VEGF expression (p=0.361). Three biochemical recurrent patients were identified as strong positive VEGF expression. CONCLUSIONS: Our study indicates that patients with advanced stage and higher Gleason sum have a trend with more VEGF expression than patients with localized disease. Identifying the angiogenesis factors especially, VEGF involved in prostatic cancer growth and understanding their regulation will lead to the developement of anti-angiogenic strategies useful for diagnostic studies and therapeutic interventions.
